Skip to content

Outcomes of Proactive Management of Children With Myelomeningocele

Urological Outcomes of Proactive Management of Children With Myelomeningocele

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06301802
Enrollment
40
Registered
2024-03-08
Start date
2024-03-04
Completion date
2026-03-15
Last updated
2024-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urologic Diseases

Keywords

myelomeningocele

Brief summary

Spina bifida birth prevalence in Africa is 0.13%. Myelomeningocele (MMC) represents the most frequent and most severe cause of NB in children. Treatment of neuropathic bladder secondary to spina bifida is an ongoing challenge. Damage of the renal parenchyma in children with NB is preventable given adequate evaluation, follow-up and proactive management. Proactive management was defined as use of clean intermittent catheterization (CIC), and/or anticholinergics at presentation, or based on initial high-risk urodynamic findings by 1 year of age. The proactive approach to treat SB (CIC and pharmacotherapy) has contributed to decreasing chronic kidney disease (CKD). Myelomeningocele is considered a complex congenital disease. Hence, a multidisciplinary team is the best choice for management of spina bifida, involving neurosurgeons, orthopedic surgeons, urologists, physical medicine and rehabilitation specialists and pediatricians. Currently, children with spina bifida in Egypt must visit multiple different locations to access the complex care they need. Here, we review our experience with patients with spina bifida who will be followed with this team with an emphasis on patients' upper urinary tract protection and decreasing urinary incontinence.

Interventions

PROCEDURECIC

clean intermittent catheterization

antimuscarinic once daily

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* all patients with myelomeningocele attending Assiut university urology hospital.

Exclusion criteria

* Associated other urological congenital anomalies (e.g., PUV or bladder exstrophy)

Design outcomes

Primary

MeasureTime frameDescription
upper tract affection2 yearspercentage of patients developing upper tract dilatation and febrile UTI

Countries

Egypt

Contacts

Primary ContactIslam Mahmoud, DR
doctorislam672@gmail.com00201090088672

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026